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	 Two	 series	 of	 amino	 acids	 conjugated	 quinazolinones	 (1a‐h	 and	 2a‐h)	were	 synthesized	 by
acid‐amine	 coupling	 and	 the	 structures	 of	 all	 the	 compounds	 were	 confirmed	 through
spectroscopic	 techniques	 such	 as	 IR,	 NMR	 and	 HRMS.	 The	 synthesized	 compounds	 were
evaluated	 for	 their	 antimicrobial,	 antioxidant	 and	 anti‐inflammatory	 activities.	 Biological
evaluation	 study	 revealed	 that,	 the	 compounds	 1f,	 2f,	 2g	 and	 1g	 showed	 good	 antioxidant
activity	 with	 50%	 of	 the	 inhibition	 concentration	 (IC50)	 values	 35,	 20,	 30	 and	 40	 µg/mL,
respectively,	much	better	 than	 the	 standard	BHT	 (IC50	 =	 45	µg/mL).	The	 compounds	1g,	2e
and	 2g	 found	 to	 have	 promising	 anti‐inflammatory	 activity	 and	 almost	 all	 the	 synthesized
compounds	 exhibited	 good	 antimicrobial	 activities	 (antibacterial	 and	 antifungal)	 against	 all
the	 selected	 pathogenic	 bacteria	 and	 fungi.	 Conjugates	 containing	 Trp,	 Tyr	 and	 Pro	 have
shown	 better	 activity	 than	 the	 rest	 of	 the	 analogues	 in	 the	 series.	 The	 structure‐activity
relationship	was	established	for	these	compounds.	
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1.	Introduction	
	
Among	 the	 different	 nitrogen	 containing	 heterocycles,	
quinazolinone	plays	an	important	role	in	medicinal	chemistry	
and	 subsequently	 have	 emerged	 as	 a	 pharmacophore.	 The	
quinazolin‐4(3H)‐one	structural	motifs	have	attracted	a	great	
deal	 of	 interest	 due	 to	 their	 ready	 accessibility,	 diverse	
chemical	reactivity	and	wide	gamut	of	biological	activities	like	
antibacterial	 [1],	 antifungal	 [2],	 antitumour	 [3],	 hypotensive	
[4],	anti‐HIV	[5],	anti‐inflammatory	[6],	etc.	Quinazolinones	are	
excellent	reservoir	of	bioactive	substances.	
Since	 the	 last	 half	 of	 the	 20th	 century,	 bacteria	 have	
developed	 resistance	 against	 currently	 available	 drugs	 and	
therefore	 it	 is	 an	 ongoing	 effort	 for	 medicinal	 chemists	 to	
synthesize	 new	 chemotherapeutic	 agents.	 Infectious	 diseases	
caused	 by	 bacteria	 and	 fungi	 affect	 millions	 of	 people	
worldwide.	 Concerted	 and	 systematic	 progresses	 to	 discover	
and	 develop	 new	 antibiotics	 are	 always	 done	 due	 to	 the	
development	of	resistance	by	the	microorganisms	to	the	drugs	
commonly	 used	 against	 them.	 The	 rapid	 rise	 in	 bacterial	
resistance	 to	 the	 traditional	antibiotics	such	as	penicillins	 [7]	
and	 tetracyclines	 [8]	had	encouraged	a	 continuing	search	 for	
new	 classes	 of	 compounds	with	novel	modes	of	 antibacterial	
activity.	
Reactive	oxygen	species	(ROS)	in	the	forms	of	superoxide	
anion	 (•O2−),	 hydroxyl	 radical	 (•OH)	 and	 hydrogen	 peroxide	
(H2O2)	 are	 generated	 from	 metabolism	 or	 environmental	
sources	 interact	 continuously	 with	 biological	 systems	 and	
their	 uncontrolled	 generation	 correlate	 directly	 with	
molecular	level	of	many	diseases	[9].	Although	a	living	system	
possesses	 several	 natural	 defense	 mechanisms,	 such	 as	
enzymes	 and	 antioxidant	 nutrients,	 which	 arrest	 the	 chain	
reaction	of	ROS	initiation	and	production,	as	these	substances	
are	unable	to	prevent	the	damage	completely	[10].	Therefore,	
there	 has	 been	 a	 considerable	 interest	 to	 develop	 non‐toxic	
and	 highly	 active	 antioxidant	 compounds	 that	 demonstrate	
measurable	health	benefits.	
Inflammation	 is	 a	 multi‐factorial	 process.	 It	 reflects	 the	
response	of	 the	organism	 to	various	 stimuli	 and	 is	 related	 to	
many	disorders	such	as	arthritis,	asthma	and	psoriasis	which	
require	prolonged	or	repeated	treatment	[11].	It	is	well	known	
that	 non‐steroidal	 anti‐inflammatory	 drugs	 (NSAIDs)	 are	
associated	 with	 several	 side	 effects	 such	 as	 gastrointestinal	
mucosal	damage,	bleeding,	intolerance	and	renal	toxicity.	
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Reagents:	1‐(3‐Dimethylaminopropyl)‐3‐ethyl‐carbodiimide	(EDCI),	1‐Hydroxy	benzotriazole	(HOBt),	N‐Methylmorpholine	(NMM).
Scheme	1
	
	
If	 inflammation	 is	 not	 combated	 in	 right	 time,	 it	 leads	 to	
multiple	deadly	diseases.	This	has	led	intense	efforts	to	search	
potent	anti‐inflammatory	agents	with	fewer	risks.		
Moreover,	 microbes	 are	 the	 root	 cause	 of	 most	 of	 the	
diseases	especially	for	the	formation	of	ROS	and	inflammatory	
lesions	 which	 progresses	 towards	 the	 plethora	 of	 problems.	
Hence,	 the	 synthesis	 of	 compounds	which	 can	 act	 against	 all	
these	propaganda	of	disorders	would	be	of	prime	interest.	On	
the	other	hand,	earlier	reports	have	shown	that	conjugation	of	
different	 amino	 acids/peptides	 to	 various	 biologically	 active	
scaffolds	 has	 fetched	 remarkable	 results,	 which	 are	 very	
promising	and	even	enthusiastic	[12‐14].	Further,	amino	acid/	
peptide	 based	 drugs	 have	 low	 toxicity,	 ample	 bioavailability	
and	 permeability,	 modest	 potency	 and	 good	 metabolic	 and	
pharmacokinetic	 properties	 [15].	 Prompted	 by	 all	 these	
observations	 and	 with	 a	 further	 interest	 to	 develop	 more	
biologically	active	compounds,	the	present	work	encompasses	
the	 synthesis	 of	 novel	 quinazolinone‐based	 amino	 acids	
analogues	 as	 promising	 antimicrobial/antioxidant/anti‐
inflammatory	agents.		
	
2.	Experimental	
	
2.1	Instrumentation	
	
All	 the	 amino	 acids	 used	 except	 glycine	 were	 of	 L‐confi‐	
guration	unless	otherwise	mentioned.	All	methyl	ester	amino	
acids,	 1‐(3‐dimethylaminopropyl)‐3‐ethylcarbodiimide.HCl	
(EDCI),	 1‐hydroxybenzotriazole	 (HOBt)	 and	 trifluoroacetic	
acid	 (TFA)	 were	 purchased	 from	 Advanced	 Chem.	 Tech.	
(Louisville,	Kentucky,	USA).	N‐Methylmorpholine	 (NMM)	was	
purchased	from	Sigma	Aldrich	(India).	All	other	chemicals	and	
reagents	 obtained	 from	 Spectrochem	 Pvt.	 Ltd.	 (India)	 and	
Rankem	 Pvt.	 Ltd.	 (India)	 were	 used	 without	 further	 purifi‐
cation.	Melting	points	were	determined	on	a	Superfit	melting	
point	 apparatus	 (India)	 and	 are	 uncorrected.	 FT‐IR	 was	
performed	 using	 a	 Jasco	 spectrometer	 (Japan)	 using	 nujol	
media.	Elemental	analysis	was	performed	by	using	VARIO	EL	
III	 CHNS	 Elementar.	 1H	 NMR	 (400	 MHz)	 and	 13C	 NMR	 (100	
MHz)	 spectra	 were	 recorded	 on	 a	 Bruker	 multinuclear	 FT‐
NMR	 spectrometer	 (Japan)	 using	 DMSO‐d6	 as	 solvent.	 The	
mass	spectra	were	recorded	on	Waters‐Synapt	G2	Q‐ToF	in	ESI	
mode	 spectrometer	 (USA).	 Progress	 of	 the	 reaction	 was	
monitored	by	TLC	using	silica	gel	coated	on	glass	plates	with	
the	 solvent	 system	 comprising	 chloroform/	 methanol/acetic	
acid	 in	 the	 ratio	 98:02:03	 (Rfa)	 and	 95:05:03	 (Rfb)	 and	 the	
compounds	on	the	TLC	plates	were	detected	by	iodine	vapors.	
	
2.2.	General	procedure	for	the	conjugation	of	methyl	esters	
of	amino	acids	to	3‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)	
propanoic	acid	(QZN	1)	and	4‐(4‐oxo‐3,4‐dihydro	
quinazolin‐2‐yl)butanoic	acid	(QZN	2)	
	
3‐(4‐Oxo‐3,4‐dihydroquinazolin‐2‐yl)propanoic	acid	 (QZN	
1)	 and	 4‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)butanoic	 acid	
(QZN	 2)	 (1	 mmol)	 dissolved	 in	 dimethyl	 formamide	 (DMF)	
separately	 (10	 mL/g	 of	 compound)	 and	 cooled	 to	 0	 °C	 was	
added	 NMM	 (1	 mmol).	 EDCI	 (1	 mmol)	 was	 added	 under	
stirring	while	maintaining	the	temperature	at	0	°C	and	stirred	
for	 15	min.	 HOBt	 (1	 mmol)	 in	 DMF	 (2	mL)	 was	 added.	 The	
reaction	mixture	was	 stirred	 for	 an	 additional	 10	min	 and	 a	
pre‐cooled	 solution	 of	 methyl	 ester	 of	 amino	 acid	 (1	 mmol)	
and	NMM	(1	mmol)	 in	DMF	was	added	 slowly.	After	20	min,	
pH	of	 the	solution	was	adjusted	 to	8	by	the	addition	of	NMM	
and	 the	 reaction	 mixture	 was	 stirred	 overnight	 at	 room	
temperature.	DMF	was	 removed	under	 reduced	pressure	and	
the	 residue	 was	 poured	 into	 about	 100	 mL	 ice‐cold	 90%	
saturated	 KHCO3	 solution	 and	 stirred	 for	 30	 min.	 The	
precipitated	 product	 was	 taken	 into	 CHCl3	 and	 washed	
sequentially	 with	 5%	 NaHCO3	 solution	 (2×20	 mL),	 water	
(2×20	mL),	0.1	N	cold	HCl	solution	(2×20	mL)	and	finally	brine	
(2×20	mL).	The	CHCl3	layer	was	dried	over	anhydrous	Na2SO4	
and	 the	 solvent	 was	 removed	 under	 reduced	 pressure.	 The	
products	 so	 obtained	 were	 recrystallized	 from	 ether/	
petroleum	 ether	 to	 get	 desired	 products	 1a‐h	 and	 2a‐h	
(Scheme	1	and	2).	
Methyl	 2‐(3‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)propan	
amido)	acetate	(1a):	Color:	White.	Yield:	81%.	Rfa	=	0.40.	Rfb	=	
0.44.	 M.p.:	 195‐196	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1630	 (C=O)	
(amide),	1675	(C=O)	(amide),	1690	(C=O)	(ester),	3345	(NH).	
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1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	12.10	(1H,	s,	QZN‐NH),	
8.10	(1H,	dd,	J	=	6.8	Hz,	1.4	Hz,	H‐5′′),	7.74	(1H,	m,	H‐7′′),	7.60	
(1H,	d,	J	=	7.6	Hz,	H‐8′′),	7.44	(1H,	m,	H‐6′′),	6.65	(1H,	d,	J	=	7.0	
Hz,	NH),	3.90	(2H,	d,	J	=	7.0	Hz,	H‐2),	3.69	(3H,	s,	‐OCH3),	2.81	
(2H,	t,	J	=	6.8	Hz,	H‐2′),	2.62	(2H,	t,	J	=	6.8	Hz,	H‐3′).	 13C	NMR	
(100	MHz,	 DMSO‐d6,	 δ,	 ppm):	 172.7	 (C,	 C‐1′),	 170.2	 (C,	 C‐1),	
161.2	(C,	C‐4′′),	156.4	(C,	C‐2′′),	148.5	(C,	C‐9′′),	133.8	(CH,	C‐
7′′),	127.2	(CH,	C‐6′′),	126.2	(CH,	C‐8′′),	125.9	(CH,	C‐5′′),	120.4	
(C,	 C‐10′′),	 51.9	 (C,	 ‐OCH3),	 45.8	 (CH2,	 C‐2),	 30.2	 (CH2,	 C‐2′),	
28.8	(CH2,	C‐1′).	HRMS	(ESI,	m/z):	290.1236	[M+1].	Anal.	calcd.	
for	C14H15N3O4:	C,	58.13,	H,	5.23;	N,	14.53.	Found:	C,	58.09;	H,	
5.12;	N,	14.46%.		
Methyl	 2‐(3‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)propan	
amido)propanoate	 (1b):	 Color:	White	 solid.	 Yield:	 71%.	 Rfa	 =	
0.36.	 Rfb	 =	 0.42.	M.p.:	 138‐140	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1638	
(C=O)	(amide),	1671	(C=O)	(amide),	1682	(C=O)	(ester),	3370	
(NH).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	11.30	(1H,	s,	QZN‐
NH),	8.23	(1H,	dd,	J	=	6.8,	1.2	Hz,	H‐5′),	7.72	(1H,	m,	H‐7′′),	7.64	
(1H,	d,	J	=	7.2	Hz,	H‐8′′),	7.45	(1H,	m,	H‐6′′),	6.68	(1H,	d,	J	=	6.8	
Hz,	NH),	4.58	(1H,	q,	J	=	6.8	Hz,	H‐2),	3.71	(3H,	s,	‐OCH3),	2.84	
(2H,	t,	J	=	7.2	Hz,	H‐2′),	2.41	(2H,	t,	J	=	7.2	Hz,	H‐3′),	1.40	(3H,	d,	
J	=	6.8	Hz,	CH3‐3).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	172.2	
(C,	C‐1′),	170.8	(C,	C‐1),	161.2	(C,	C‐4′′),	156.7	(C,	C‐2′′),	148.7	
(C,	C‐9′′),	134.1	(CH,	C‐7′′),	127.7	(CH,	C‐6′′),	126.6	(CH,	C‐8′′),	
126.1	(CH,	C‐5′′),	120.7	(C,	C‐10′′),	51.6	(C,	‐OCH3),	48.9	(CH,	C‐
2),	 33.7	 (CH2,	 C‐2′),	 26.8	 (CH2,	 C‐1′),	 16.8	 (CH3,	 C‐3).	 HRMS	
(ESI,	 m/z):	 304.2145	 [M+1].	 Anal.	 calcd.	 for	 C15H17N3O4:	 C,	
59.40,	H,	5.65;	N,	13.85.	Found:	C,	59.31;	H,	5.54;	N,	13.73%.	
Methyl	 3‐methyl‐2‐(3‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)	
propanamido)butanoate	 (1c):	 Color:	White	 solid.	 Yield:	 86%.	
Rfa	 =	 0.43.	 Rfb	 =	 0.47.	 M.p.:	 180‐181	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	
1633	(C=O)	(amide),	1685	(C=O)	(amide),	1649	(C=O)	(ester),	
3320	(NH).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	10.92	(1H,	s,	
QZN‐NH),	8.26	 (1H,	dd,	 J	=	6.8,	 1.2	Hz,	H‐5′),	7.73	 (1H,	m,	H‐
7′′),	7.64	(1H,	d,	J	=	8.0	Hz,	H‐8′′),	7.44	(1H,	m,	H‐6′′),	6.54	(1H,	
d,	 J	 =	8.4	Hz,	NH),	4.60	 (1H,	q,	 J	 =	8.4	Hz,	H‐2),	 3.72	 (3H,	 s,	 ‐
OCH3),	3.07	(2H,	t,	J	=	6.8	Hz,	H‐2′),	2.84	(2H,	t,	J	=	6.8	Hz,	H‐3′),	
2.20	(1H,	m,	H‐3),	0.90	(6H,	d,	J	=	6.8	Hz,	(CH3)2).	13C	NMR	(100	
MHz,	DMSO‐d6,	 δ,	 ppm):	172.2	 (C,	C‐1′),	172.0	 (C,	C‐1),	 161.8	
(C,	 C‐4′′),	 156.1	 (C,	 C‐2′′),	 148.4	 (C,	 C‐9′′),	 134.1	 (CH,	 C‐7′′),	
126.8	(CH,	C‐6′′),	126.1	(CH,	C‐8′′),	125.7	(CH,	C‐5′′),	120.7	(C,	
C‐10′′),	 57.4	 (CH,	 C‐2),	 51.8	 (C,	 ‐OCH3),	 33.7	 (CH,	 C‐3),	 33.2	
(CH2,	 C‐2′),	 29.7	 (CH2,	 C‐1′),	 18.7	 (CH3,	 C‐4),	 18.4	 (CH3,	 C‐5).	
HRMS	(ESI,	m/z):	332.0829	[M+1].	Anal.	calcd.	for	C17H21N3O4:	
C,	61.62,	H,	6.39;	N,	12.68.	Found:	C,	61.49;	H,	6.26;	N,	12.56.	
Methyl	 3‐hydroxy‐2‐(3‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)	
propanamido)propanoate	 (1d	 ):	 Color:	 Brown	 gummy.	 Yield:	
71%.	 Rfa	 =	 0.44.	 Rfb	 =	 0.49.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1627	 (C=O)	
(amide),	1638	(C=O)	(amide),	1671	(C=O)	(ester),	3318	(NH).	
1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	11.09	(1H,	s,	QZN‐NH),	
8.25	 (1H,	 dd,	 J	=	 6.8,	 1.4	 Hz,	 H‐5′′),	 7.71	 (1H,	m,	H‐7′′),	 7.63	
(1H,	d,	J	=	8.0	Hz,	H‐8′′),	7.43	(1H,	m,	H‐6′′),	6.67	(1H,	d,	J	=	7.2	
Hz,	NH),	5.78	(1H,	s,	OH),	4.52	(1H,	q,	J	=	7.2	Hz,	H‐2),	4.10	(2H,	
d,	J	=	7.2	Hz,	H‐3),	3.71	(3H,	s,	‐OCH3),	3.14	(2H,	t,	J	=	7.2	Hz,	H‐
2′),	2.84	(2H,	t,	J	=	7.2	Hz,	H‐3′).	13C	NMR	(100	MHz,	DMSO‐d6,	
δ,	ppm):	171.7	(C,	C‐1′),	170.7	(C,	C‐1),	161.7	(C,	C‐4′′),	156.7	
(C,	C‐2′′),	148.1	 (C,	C‐9′′),	133.8	 (CH,	C‐7′′),	128.0	 (CH,	C‐6′′),	
126.2	(CH,	C‐8′′),	125.9	(CH,	C‐5′′),	120.8	(C,	C‐10′′),	64.1	(CH2,	
C‐3),	57.2	(CH,	C‐2),	51.7	(C,	‐OCH3),	30.6	(CH2,	C‐1′),	29.4	(CH2,	
C‐2′).	 HRMS	 (ESI,	 m/z):	 320.1053	 [M+1].	 Anal.	 calcd.	 for	
C15H17N3O5:	C,	56.42,	H,	5.37;	N,	13.16.	Found:	C,	56.35;	H,	5.26;	
N,	13.06%.	
Methyl	 2‐(3‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)propan	
amido)‐3‐phenylpropanoate	 (1e):	 Color:	 White	 solid.	 Yield:	
72%.	Rfa	=	0.36.	Rfb	=	0.41.	M.p.:	174‐176	°C.	FT‐IR	(KBr,	ν,	cm‐
1):	 1639	 (C=O)	 (amide),	 1652	 (C=O)	 (amide),	 1684	 (C=O)	
(ester),	 3302	 (NH).	 1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
11.30	(1H,	s,	QZN‐NH),	8.24	(1H,	d,	J	=	8.0,	1.4	Hz,	H‐5′′),	7.73	
(1H,	m,	H‐7′′),	7.61	(1H,	d,	J	=	7.8	Hz,	H‐8′′),	7.46	(1H,	m,	H‐6′′),	
7.12	(3H,	m,	H‐6,	H‐6′	&	H‐7)	7.05	(2H,	m,	H‐5,	H‐5′),	6.78	(1H,	
d,	 J	 =	6.2	Hz,	NH),	4.90	 (1H,	q,	 J	 =	6.2	Hz,	H‐2),	 3.69	 (3H,	 s,	 ‐
OCH3),	3.22	(2H,	d,	J	=	6.2	Hz,	H‐3),	2.81	(2H,	t,	J	=	7.2	Hz,	H‐2′),	
2.44	 (2H,	 t,	 J	=	7.2	Hz,	H‐3′).	 13C	NMR	(100	MHz,	DMSO‐d6,	δ,	
ppm):	172.0	(C,	C‐1′),	171.0	(C,	C‐1),	161.5	(C,	C‐4′′),	156.4	(C,	
C‐2′′),	148.7	 (C,	C‐9′′),	137.1	 (C,	C‐4),	134.1	 (CH,	C‐7′′),	128.9	
(CH,	 C‐6,	 C‐6′),	 128.1	 (CH,	 C‐5,	 C‐5′),	 126.7	 (CH,	 C‐6′′),	 126.4	
(CH,	C‐8′′),	125.8	(CH,	C‐5′′),	125.6	(CH,	C‐5),	120.8	(C,	C‐10′′),	
53.5	(CH,	C‐2),	51.7	(C,	‐OCH3),	36.7	(CH2,	C‐3),	31.0	(CH2,	C‐1′),	
29.4	(CH2,	C‐2′).	HRMS	(ESI,	m/z):	380.0851	[M+1].	Anal.	calcd.	
for	C21H21N3O4:	C,	66.48,	H,	5.58;	N,	11.08.	Found:	C,	66.40;	H,	
5.43;	N,	11.01%.		
Methyl	 3‐(4‐hydroxyphenyl)‐2‐(3‐(4‐oxo‐3,4‐dihydroquina	
zolin‐2‐yl)propanamido)	 propanoate	 (1f):	 Color:	 Brown	 solid.	
Yield:	75%.	Rfa	=	0.37.	Rfb	=	0.42.	M.p.:	178‐179	°C.	FT‐IR	(KBr,	
ν,	cm‐1):	1632	(C=O)	(amide),	1650	(C=O)	(amide),	1670	(C=O)	
(ester),	 3310	 (NH).	 1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
11.12	(1H,	s,	QZN‐NH),	8.24	(1H,	dd,	J	=	6.8,	1.4	Hz,	H‐5′′),	7.73	
(1H,	m,	H‐7′′),	7.65	(1H,	d,	J	=	8.0	Hz,	H‐8′′),	7.44	(1H,	m,	H‐6′′),	
7.14	(2H,	m,	H‐5,	H‐5′),	6.92	(2H,	m,	H‐6,	H‐6′),	6.65	(1H,	d,	J	=	
6.8	Hz,	NH),	5.88	(1H,	s,	OH),	4.54	(1H,	q,	J	=	6.8	Hz,	H‐2),	3.68	
(3H,	s,	‐OCH3),	3.21	(2H,	d,	J	=	6.8	Hz,	H‐3),	2.81	(2H,	t,	J	=	6.8	
Hz,	 H‐2′),	 2.71	 (2H,	 t,	 J	 =	 6.8	 Hz,	 H‐3′).	 13C	 NMR	 (100	 MHz,	
DMSO‐d6,	δ,	ppm):	171.7	(C,	C‐1′),	170.8	 (C,	C‐1),	161.7	 (C,	C‐
4′′),	156.7	(C,	C‐2′′),	153.8	(C,	C‐7),	148.8	(C,	C‐9′′),	134.7	(CH,	
C‐7′′),	 130.1	 (C,	 C‐4),	 129.8	 (CH,	 C‐5,	 C‐5′),	 127.2	 (CH,	 C‐6′),	
126.7	(CH,	C‐8′′),	125.9	(CH,	C‐5′′),	120.7	(C,	C‐10′′),	115.9	(C,	
C‐6,	C‐6′),	58.2	(CH,	C‐2),	51.7	(C,	‐OCH3),	37.8	(CH2,	C‐3),	30.3	
(CH2,	C‐1′),	29.8	(CH2,	C‐2′).	HRMS	(ESI,	m/z):	396.1351	[M+1].	
Anal.	calcd.	 for	C21H21N3O5:	C,	63.79,	H,	5.35;	N,	10.63.	Found:	
C,	63.68;	H,	5.22;	N,	10.54%.	
Methyl	3‐(1H‐indol‐3‐yl)‐2‐(3‐(4‐oxo‐3,4‐dihydroquinazolin‐
2‐yl)propanamido)	propanoate	(1g):	Color:	Brown	solid.	Yield:	
79%.	Rfa	=	0.52.	Rfb	=	0.59.	M.p.:	109‐110	°C.	FT‐IR	(KBr,	ν,	cm‐
1):	 1641	 (C=O)	 (amide),	 1678	 (C=O)	 (amide),	 1690	 (C=O)	
(ester),	 3310	 (NH).	 1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
12.15	(1H,	s,	QZN‐NH),	10.87	(1H,	s,	Indole‐NH),	8.43	(1H,	dd,	J	
=	6.8,	1.2	Hz,	H‐5′′),	8.08	(1H,	d,	J	=	6.8	Hz,	H‐6),	7.95	(1H,	m,	H‐
7′′),	7.74	(1H,	d,	J	=	6.4	Hz,	H‐8′′),	7.53	(1H,	m,	H‐6′′),	7.47	(1H,	
t,	J	=	8.4	Hz,	H‐7),	7.53	(1H,	d,	J	=	7.6	Hz,	H‐9),	7.18	(1H,	s,	H‐5),	
7.07	(1H,	m,	H‐8),	7.00	(1H,	d,	J	=	7.2	Hz,	NH),	4.53	(1H,	q,	J	=	
7.2	Hz,	H‐2),	3.61	(3H,	s,	‐OCH3),	3.18	(2H,	d,	J	=	7.2	Hz,	H‐3),	
2.82	(2H,	 t,	 J	=	6.8	Hz,	H‐2′),	2.70	(2H,	 t,	 J	=	6.8	Hz,	H‐3′).	 13C	
NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	172.3	(C,	C‐1′),	169.4	(C,	C‐
1),	161.7	(C,	C‐4′′),	156.2	(C,	C‐2′′),	148.2	(C,	C‐9′′),	137.3	(C,	C‐
10),	133.2	(CH,	C‐7′′),	131.0	(CH,	C‐6′′),	128.8	(C,	C‐11),	127.1	
(CH,	C‐8′′),	126.1	(CH,	C‐5′′),	123.5	(CH,	C‐5),	121.2	(CH,	C‐8),	
120.9	(C,	C‐10′′),	116.6	(CH,	C‐6),	114.6	(CH,	C‐7),	110.7	(CH,	C‐
9),	108.9	(C,	C‐4),	56.8	(CH,	C‐2),	51.8	(C,	‐OCH3),	36.3	(CH2,	C‐
3),	 34.7	 (CH2,	 C‐2′),	 32.3	 (CH2,	 C‐1′).	 HRMS	 (ESI,	 m/z):	
419.2134	[M+1].	Anal.	calcd.	for	C23H22N4O4:	C,	66.02,	H,	5.30;	
N,	13.39.	Found:	C,	66.01;	H,	5.20;	N,	13.29%.		
Methyl	 1‐(3‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)propanoyl)	
pyrrolidine‐2‐carboxylate	 (1h):	 Color:	 White	 gummy.	 Yield:	
83%.	 Rfa	 =	 0.41.	 Rfb	 =	 0.45.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1634	 (C=O)	
(amide),	 1657	 (C=O)	 (amide),	 1680	 (C=O)	 (ester).	 1H	 NMR	
(400	MHz,	DMSO‐d6,	δ,	ppm):	12.02	(1H,	s,	QZN‐NH),	8.27	(1H,	
dd,	J	=	6.8,	1.2	Hz,	H‐5′′),	7.72	(1H,	m,	H‐7′′),	7.70	(1H,	d,	J	=	7.0	
Hz,	H‐8′′),	7.45	(1H,	m,	H‐6′′),	4.58	(1H,	t,	J	=	6.8	Hz,	αCH),	3.71	
(3H,	s,	‐OCH3),	3.53	(2H,	t,	J	=	6.8	Hz,	δCH2),	2.78	(2H,	t,	J	=	7.2	
Hz,	H‐2′),	2.48	(2H,	t,	J	=	7.2	Hz,	H‐3′),	2.18	(2H,	m,	βCH2),	2.01	
(2H,	m,	γCH2).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	171.8	(C,	
C‐1′),	170.0	(C,	C‐1),	161.6	(C,	C‐4′′),	156.6	(C,	C‐2′′),	148.7	(C,	
C‐9′′),	 134.1	 (CH,	 C‐7′′),	 127.5	 (CH,	 C‐6′′),	 126.7	 (CH,	 C‐8′′),	
125.8	 (CH,	 C‐5′′),	 120.4	 (C,	 C‐10′′),	 66.4	 (C,	 αCH),	 51.8	 (C,	 ‐
OCH3),	46.5	(C,	δCH2),	30.7	(CH2,	C‐1′),	29.9	(C,	βCH2),	28.3	(CH2,	
C‐2′),	24.3	 (C,	 γCH2).	HRMS	(ESI,	m/z):	330.2631	[M+1].	Anal.	
calcd.	 for	 C17H19N3O4:	 C,	 62.00,	 H,	 5.81;	 N,	 12.76.	 Found:	 C,	
61.95;	H,	5.70;	N,	12.68%.	
Methyl	2‐(4‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)butanamido)	
acetate	 (2a):	 Color:	White	 solid.	 Yield:	 77%.	 Rfa	 =	 0.37.	 Rfb	 =	
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0.41.	 M.p.:	 184‐185	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1627	 (C=O)	
(amide),	 1641	 (C=O)	 (amide),	 1660	 (CO)	 (ester),	 3327	 (NH).	
1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	12.16	(1H,	s,	QZN‐NH),	
8.09	 (1H,	 dd,	 J	=	 6.8,	 1.4	 Hz,	 H‐5′′),	 7.76	 (1H,	m,	H‐7′′),	 7.61	
(1H,	d,	J	=	7.6	Hz,	H‐8′′),	7.46	(1H,	m,	H‐6′′),	6.67	(1H,	d,	J	=	6.8	
Hz,	NH),	3.89	(2H,	d,	J	=	6.8	Hz,	H‐2),	3.71	(3H,	s,	‐OCH3),	2.83	
(2H,	t,	J	=	6.8	Hz,	H‐2′),	2.62	(2H,	t,	J	=	6.8	Hz,	H‐4′),	2.24	(2H,	t,	
J	=	6.8	Hz,	H‐3′).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	172.7	
(C,	C‐1′),	170.2	(C,	C‐1),	161.2	(C,	C‐4′′),	156.2	(C,	C‐2′′),	148.4	
(C,	C‐9′′),	133.2	(CH,	C‐7′′),	127.2	(CH,	C‐6′′),	126.8	(CH,	C‐8′′),	
126.1	(CH,	C‐5′′),	120.2	(C,	C‐10′′),	51.8	(C,	‐OCH3),	44.7	(CH2,	
C‐2),	33.7	(CH2,	C‐3′),	31.9	(CH2,	C‐1′),	25.3	(CH2,	C‐2′).	HRMS	
(ESI,	 m/z):	 304.1065	 [M+1].	 Anal.	 calcd.	 for	 C15H17N3O4:	 C,	
59.40,	H,	5.65;	N,	13.85.	Found:	C,	59.32;	H,	5.54;	N,	13.77%.	
Methyl	 2‐(4‐(4‐oxo‐3,	 4‐dihydroquinazolin‐2‐yl)butan	
amido)propanoate	 (2b):	 Color:	White	 solid.	 Yield:	 85%.	 Rfa	 =	
0.35.	 Rfb	 =	 0.41.	M.p.:	 187‐188	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1626	
(C=O)	(amide),	1635	(C=O)	(amide),	1668	(C=O)	(ester),	3333	
(NH).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	11.32	(1H,	s,	QZN‐
NH),	8.25	(1H,	dd,	J	=	6.8,	1.2	Hz,	H‐5′),	7.74	(1H,	m,	H‐7′′),	7.65	
(1H,	d,	J	=	7.6	Hz,	H‐8′′),	7.44	(1H,	m,	H‐6′′),	6.66	(1H,	d,	J	=	7.6	
Hz,	NH),	4.60	(1H,	q,	J	=	7.6	Hz,	H‐2),	3.75	(3H,	s,	‐OCH3),	2.86	
(2H,	t,	J	=	7.0	Hz,	H‐2′),	2.38	(2H,	t,	J	=	7.0	Hz,	H‐4′),2.22	(2H,	q,	
J	=	7.0	Hz,	H‐3′),	1.41	(3H,	d,	J	=	7.6	Hz,	CH3‐3).	13C	NMR	(100	
MHz,	DMSO‐d6,	 δ,	 ppm):	173.2	 (C,	C‐1′),	171.5	 (C,	C‐1),	 161.7	
(C,	 C‐4′′),	 156.9	 (C,	 C‐2′′),	 148.8	 (C,	 C‐9′′),	 134.1	 (CH,	 C‐7′′),	
126.7	(CH,	C‐6′′),	125.8	(CH,	C‐8′′),	125.6	(CH,	C‐5′′),	120.8	(C,	
C‐10′′),	 51.7	 (C,	 ‐OCH3),	 47.4	 (CH,	 C‐2),	 34.0	 (CH2,	 C‐3′),	 33.6	
(CH2,	C‐1′),	22.5	(CH2,	C‐2′),	16.8	(CH3,	C‐3).	HRMS	(ESI,	m/z):	
318.0734[M+1].	Anal.	 calcd.	 for	C16H19N3O4:	C,	 60.56,	H,	6.03;	
N,	13.24.	Found:	C,	60.47;	H,	5.90;	N,	13.18%.	
Methyl	 3‐methyl‐2‐(4‐(4‐oxo‐3,	 4‐dihydroquinazolin‐2‐yl)	
butanamido)butanoate	(2c):	Color:	White	solid.	Yield:	79%.	Rfa	
=	0.38.	Rfb	=	0.43.	M.p.:	194‐195	°C.	FT‐IR	(KBr,	ν,	cm‐1):	1637	
(C=O)	(amide),	1670	(C=O)	(amide),	1667	(C=O)	(ester),	3340	
(NH).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	10.94	(1H,	s,	QZN‐
NH),	8.26	(1H,	dd,	J	=	6.8,	1.0	Hz,	H‐5′),	7.75	(1H,	m,	H‐7′′),	7.68	
(1H,	d,	J	=	8.0	Hz,	H‐8′′),	7.45	(1H,	m,	H‐6′′),	6.46	(1H,	d,	J	=	8.4	
Hz,	NH),	4.59	(1H,	q,	J	=	8.4	Hz,	H‐2),	3.76	(3H,	s,	‐OCH3),	2.84	
(2H,	t,	J	=	7.0	Hz,	H‐2′),	2.42	(2H,	t,	J	=	7.0	Hz,	H‐4′),	2.21	(3H,	
m,	 H‐3′,	H‐3),	 0.95	 (6H,	 d,	 J	 =	 6.8	 Hz,	 (CH3)2).	 13C	 NMR	 (100	
MHz,	DMSO‐d6,	 δ,	 ppm):	172.1	 (C,	C‐1′),	172.0	 (C,	C‐1),	 161.7	
(C,	 C‐4′′),	 156.8	 (C,	 C‐2′′),	 148.6	 (C,	 C‐9′′),	 134.2	 (CH,	 C‐7′′),	
126.6	(CH,	C‐6′′),	125.9	(CH,	C‐8′′),	125.6	(CH,	C‐5′′),	120.8	(C,	
C‐10′′),	 57.3	 (CH,	 C‐2),	 51.5	 (C,	 ‐OCH3),	 33.9	 (CH2,	 C‐3′),	 33.7	
(CH,	 C‐3),	 29.7	 (CH2,	 C‐1′),	 22.7	 (CH2,	 C‐2′),	 18.9	 (CH3,	 C‐4),	
18.2	(CH3,	C‐5).	HRMS	(ESI,	m/z):	346.1044	[M+1].	Anal.	calcd.	
for	C18H23N3O4:	C,	62.60,	H,	6.66;	N,	12.17.	Found:	C,	62.48;	H,	
6.57;	N,	12.08%.	
Methyl	 3‐hydroxy‐2‐(4‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐
yl)butanamido)propanoate	 (2d):	 Color:	 Brown	 gummy.	 Yield:	
70%.	 Rfa	 =	 0.40.	 Rfb	 =	 0.46.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1630	 (C=O)	
(amide),	1641	(C=O)	(amide),	1677	(C=O)	(ester),	3340	(NH).	
1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	11.12	(1H,	s,	QZN‐NH),	
8.23	 (1H,	 dd,	 J	=	 6.8,	 1.4	 Hz,	 H‐5′′),	 7.70	 (1H,	m,	H‐7′′),	 7.61	
(1H,	d,	J	=	7.8	Hz,	H‐8′′),	7.44	(1H,	m,	H‐6′′),	6.65	(1H,	d,	J	=	7.2	
Hz,	NH),	5.42	(1H,	s,	OH),	4.54	(1H,	q,	J	=	7.2	Hz,	H‐2),	4.13	(2H,	
d,	J	=	7.2	Hz,	H‐3),	3.69	(3H,	s,	‐OCH3),	3.17	(2H,	t,	J	=	7.4	Hz,	H‐
2′),	2.83	(2H,	t,	J	=	7.4	Hz,	H‐4′),	2.23	(2H,	q,	J	=	7.4	Hz,	H‐3′).	
13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	171.7	(C,	C‐1′),	170.3	(C,	
C‐1),	 161.8	 (C,	 C‐4′′),	 156.2	 (C,	 C‐2′′),	 148.7	 (C,	 C‐9′′),	 134.1	
(CH,	 C‐7′′),	 127.2	 (CH,	 C‐6′′),	 126.9	 (CH,	 C‐8′′),	 126.2	 (CH,	 C‐
5′′),	120.4	(C,	C‐10′′),	66.2	(CH2,	C‐3),	57.3	(CH,	C‐2),	51.9	(C,	‐
OCH3),	33.6	(CH2,	C‐3′),	31.8	(CH2,	C‐1′),	26.1	(CH2,	C‐2′).	HRMS	
(ESI,	 m/z):	 334.1642	 [M+1].	 Anal.	 calcd.	 for	 C16H19N3O5:	 C,	
57.65,	H,	5.70;	N,	12.61.	Found:	C,	57.52;	H,	5.63;	N,	12.56%.	
Methyl	 2‐(4‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)butan	
amido)‐3‐phenylpropanoate	 (2e):	 Color:	 White	 solid.	 Yield:	
85%.	Rfa	=	0.39.	Rfb	=	0.45.	M.p.:	182‐183	°C.	FT‐IR	(KBr,	ν,	cm‐
1):	 1631	 (C=O)	 (amide),	 1667	 (C=O)	 (amide),	 1678	 (C=O)	
(ester),	 3320	 (NH).	 1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
11.35	(1H,	s,	QZN‐NH),	8.26	(1H,	d,	J	=	8.0,	1.4	Hz,	H‐5′′),	7.72	
(1H,	m,	H‐7′′),	7.58	(1H,	d,	J	=	8.0	Hz,	H‐8′′),	7.45	(1H,	m,	H‐6′′),	
7.17	(3H,	m,	H‐6,	H‐6′	&	H‐7)	7.04	(2H,	m,	H‐5,	H‐5′),	6.80	(1H,	
d,	 J	 =	7.2	Hz,	NH),	4.94	 (1H,	q,	 J	 =	7.2	Hz,	H‐2),	 3.68	 (3H,	 s,	 ‐
OCH3),	3.17	(2H,	d,	J	=	7.2	Hz,	H‐3),	3.04	(2H,	t,	J	=	6.8	Hz,	H‐2′),	
2.78	(2H,	 t,	 J	=	6.8	Hz,	H‐4′),	2.18	(2H,	 t,	 J	=	6.8	Hz,	H‐3′).	 13C	
NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	172.0	(C,	C‐1′),	171.8	(C,	C‐
1),	161.9	(C,	C‐4′′),	156.6	(C,	C‐2′′),	148.7	(C,	C‐9′′),	135.6	(C,	C‐
4),	134.6	(CH,	C‐7′′),	129.1	(CH,	C‐5,	C‐5′),	128.5	(CH,	C‐6,	C‐6′),	
127.1	 (CH,	 C‐6′′),	 126.9	 (CH,	 C‐8′′),	 126.6	 (CH,	 C‐5′′),	 125.9	
(CH,	C‐7),	120.9	(C,	C‐10′′),	53.2	(CH,	C‐2),	51.8	(C,	‐OCH3),	37.8	
(CH2,	 C‐3),	 32.5	 (CH2,	 C‐3′),	 30.5	 (CH2,	 C‐1′),	 27.2	 (CH2,	 C‐2′).	
HRMS	(ESI,	m/z):	394.1044	[M+1].	Anal.	calcd.	for	C22H23N3O4:	
C,	67.16,	H,	5.89;	N,	10.68.	Found:	C,	67.08;	H,	5.76;	N,	10.57%.	
Methyl‐3‐(4‐hydroxyphenyl)‐2‐(4‐(4‐oxo‐3,	 4‐dihydroquina	
zolin‐2‐yl)butanamido)‐propanoate	 (2f):	 Color:	 Brown	 solid.	
Yield:	77%.	Rfa	=	0.41.	Rfb	=	0.46.	M.p.:	176‐177	°C.	FT‐IR	(KBr,	
ν,	cm‐1):	1637	(C=O)	(amide),	1669	(C=O)	(amide),	1679	(C=O)	
(ester),	 3326	 (NH).	 1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
11.09	(1H,	s,	QZN‐NH),	8.26	(1H,	dd,	J	=	6.8,	1.4	Hz,	H‐5′′),	7.74	
(1H,	m,	H‐7′′),	7.64	(1H,	d,	J	=	8.0	Hz,	H‐8′′),	7.43	(1H,	m,	H‐6′′),	
7.12	(2H,	m,	H‐5,	H‐5′),	6.92	(2H,	m,	H‐6,	H‐6′),	6.67	(1H,	d,	J	=	
6.8	Hz,	NH),	5.70	(1H,	s,	OH),	4.53	(1H,	q,	J	=	6.8	Hz,	H‐2),	3.69	
(3H,	s,	‐OCH3),	3.24	(2H,	d,	J	=	6.8	Hz,	H‐3),	2.84	(2H,	t,	J	=	7.4	
Hz,	H‐2′),	2.41	(2H,	t,	J	=	7.4	Hz,	H‐4′),	2.20	(2H,	t,	J	=	7.4	Hz,	H‐
3′).	 13C	 NMR	 (100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 172.1	 (C,	 C‐1′),	
170.2	(C,	C‐1),	161.8	(C,	C‐4′′),	156.7	(C,	C‐2′′),	153.6	(C,	C‐7),	
148.3	(C,	C‐9′′),	133.8	(CH,	C‐7′′),	130.7	(C,	C‐4),	130.2	(CH,	C‐
5,	C‐5′),	126.9	 (CH,	C‐6′′),	126.6	 (CH,	C‐8′′),	125.9	 (CH,	C‐5′′),	
120.8	(C,	C‐10′′),	116.9	(C,	C‐6,	C‐6′),	57.3	(CH,	C‐2),	51.9	(C,	‐
OCH3),	37.3	 (CH2,	C‐3),	34.4	 (CH2,	C‐3′),	29.8	 (CH2,	C‐1′),	22.7	
(CH2,	C‐2′).	HRMS	(ESI,	m/z):	410.0965	[M+1].	Anal.	calcd.	for	
C22H23N3O5:	C,	64.54,	H,	5.66;	N,	10.26.	Found:	C,	64.42;	H,	5.51;	
N,	10.13%.	
Methyl‐3‐(1H‐indol‐3‐yl)‐2‐(4‐(4‐oxo‐3,	4‐dihydroquinazo	
lin‐2‐yl)butanamido)	 propanoate	 (2g):	 Color:	 Reddish	 solid.	
Yield:	71%.	Rfa	=	0.53.	Rfb	=	0.60.	M.p.:	135‐136	°C.	FT‐IR	(KBr,	
ν,	cm‐1):	1640	(C=O)	(amide),	1672	(C=O)	(amide),	1680	(C=O)	
(ester),	 3338	 (NH).	 1H	 NMR	 (400	 MHz,	 DMSO‐d6,	 δ,	 ppm):	
12.10	(1H,	s,	QZN‐NH),	10.92	(1H,	s,	Indole‐NH),	8.40	(1H,	dd,	J	
=	6.8,	1.2	Hz,	H‐5′′),	8.12	(1H,	d,	J	=	7.6	Hz,	H‐6),	7.90	(1H,	m,	H‐
7′′),	7.70	(1H,	d,	J	=	8.0	Hz,	H‐8′′),	7.51	(1H,	m,	H‐6′′),	7.42	(1H,	
m,	H‐7),	7.30	(1H,	d,	J	=	6.8	Hz,	H‐9),	7.19	(1H,	s,	H‐5),	7.07	(1H,	
t,	J	=	6.0	Hz,	H‐8),	7.02	(1H,	d,	J	=	6,8	Hz,	NH),	4.55	(1H,	q,	J	=	
6.8	Hz,	H‐2),	3.68	(3H,	s,	‐OCH3),	3.20	(2H,	d,	J	=	6.8	Hz,	H‐3),	
2.88	(2H,	t,	J	=	6.2	Hz,	H‐2′),	2.40	(2H,	t,	J	=	6.2	Hz,	H‐4′),	2.21	
(2H,	q,	J	=	6.2	Hz,	H‐3′).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	ppm):	
172.9	(C,	C‐1′),	170.2	(C,	C‐1),	161.2	(C,	C‐4′′),	156.2	(C,	C‐2′′),	
148.2	(C,	C‐9′′),	138.2	(C,	C‐10),	134.1	(CH,	C‐7′′),	130.2	(CH,	C‐
6′′),	128.2	(C,	C‐11),	127.2	(CH,	C‐8′′),	126.9	(CH,	C‐5′′),	123.2	
(CH,	 C‐5),	 121.3	 (CH,	 C‐8),	 120.9	 (C,	 C‐10′′),	 118.1	 (CH,	 C‐6),	
117.1	(CH,	C‐7),	110.8	(CH,	C‐9),	108.7	(C,	C‐4),	57.4	(CH,	C‐2),	
51.7	(C,	‐OCH3),	36.7	(CH2,	C‐3),	34.9	(CH2,	C‐3′),	31.9	(CH2,	C‐
2′),	26.9	 (CH2,	C‐1′).	HRMS	(ESI,	m/z):	 433.1092	 [M+1].	Anal.	
calcd.	 for	 C24H24N4O4:	 C,	 66.65,	 H,	 5.59;	 N,	 12.96.	 Found:	 C,	
66.57;	H,	5.47;	N,	12.88%.		
Methyl	 1‐(4‐(4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)butanoyl)	
pyrrolidine‐2‐carboxylate	 (2h):	 Color:	 White	 gummy.	 Yield:	
87%.	 Rfa	 =	 0.34.	 Rfb	 =	 0.40.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1640	 (C=O)	
(amide),	 1660	 (C=O)	 (amide),	 1685	 (C=O)	 (ester).	 1H	 NMR	
(400	MHz,	DMSO‐d6,	δ,	ppm):	11.10	(1H,	s,	QZN‐NH),	8.24	(1H,	
dd,	J	=	6.8,	1.2	Hz,	H‐5′′),	7.68	(1H,	m,	H‐7′′),	7.62	(1H,	d,	J	=	7.0	
Hz,	H‐8′′),	7.42	(1H,	m,	H‐6′′),	4.61	(1H,	q,	J	=	5.6	Hz,	αCH),	3.73	
(3H,	s,	‐OCH3),	3.58	(2H,	t,	J	=	8.6	Hz,	δCH2),	3.16	(2H,	t,	J	=	7.2	
Hz,	H‐2′),	2.87	(2H,	t,	J	=	7.2	Hz,	H‐4′),	2.18	(2H,	m,	βCH2),	2.06	
(2H,	m,	γCH2),	2.03	(2H,	q,	J	=	7.2	Hz,	H‐3′).	13C	NMR	(100	MHz,	
DMSO‐d6,	δ,	ppm):	171.2	(C,	C‐1′),	170.2	 (C,	C‐1),	161.7	 (C,	C‐
4′′),	 156.2	 (C,	 C‐2′′),	 148.3	 (C,	 C‐9′′),	 133.7	 (CH,	 C‐7′′),	 127.2	
(CH,	 C‐6′′),	 126.6	 (CH,	 C‐8′′),	 125.9	 (CH,	 C‐5′′),	 120.7	 (C,	 C‐
10′′),	65.9	(C,	αCH),	51.7	(C,	‐OCH3),	46.1	(C,	δCH2),	33.7	(CH2,	C‐
3′),	 31.8	 (CH2,	 C‐1′),	 29.7	 (C,	 βCH2),	 26.7	 (CH2,	 C‐2′),	 24.7	 (C,	
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γCH2).	 HRMS	 (ESI,	 m/z):	 344.1342	 [M+1].	 Anal.	 calcd.	 for	
C18H21N3O4:	C,	62.96,	H,	6.16;	N,	12.24.	Found:	C,	62.81;	H,	6.08;	
N,	12.16%.	
	
 
 
 
	
Scheme	2	
	
	
2.3.	Biological	evaluation		
	
2.3.1.	Antimicrobial	activity	
	
2.3.1.1.	Antibacterial	activity	
	
In	vitro	antibacterial	activity	was	evaluated	against	human	
pathogens	of	Gram	negative	organisms	namely	S.	typhimurium,	
E.	aerogenes,	E.	coli	and	K.	pneumoniae	by	agar	well	diffusion	
method	 [16].	 The	microorganisms	 were	 inoculated	 in	 to	 the	
sterilized	nutrient	broth	and	maintained	at	37	°C	for	24	hours.	
On	 the	 day	 of	 testing,	 bacteria	 were	 subcultured	 separately	
into	25	mL	of	sterilized	nutrient	broth.	Inoculated	subcultured	
broths	 were	 kept	 at	 room	 temperature	 for	 the	 growth	 of	
inoculums.	 Each	 test	 compounds	 (1a‐h,	 2a‐h)	 and	 standard	
drug	(Streptomycin)	of	10	mg	was	dissolved	in	10	mL	of	DMSO	
to	get	a	concentration	of	1	mg/mL	and	further	diluted	to	get	a	
final	 concentration	 of	 30	 μg/mL.	 About	 15‐20	mL	 of	 molten	
nutrient	agar	was	poured	into	each	of	 the	sterile	plates.	With	
the	 help	 of	 cork	 borer	 of	 6	 mm	 diameter,	 the	 cups	 were	
punched	and	scooped	out	of	the	set	agar	and	the	plates	were	
inoculated	 with	 the	 suspension	 of	 particular	 organism	 by	
spread	 plate	 technique.	 The	 cups	 of	 inoculated	 plates	 were	
then	 filled	 with	 0.1	 mL	 of	 the	 test	 solution,	 streptomycin	
solution	 and	 DMSO	 (negative	 control).	 The	 plates	 were	
allowed	 to	 stay	 for	 24	 hours	 at	 37	 °C	 and	 zone	 of	 inhibition	
(mm)	was	then	measured.	
	
2.3.1.2	Antifungal	activity	
	
In	 vitro	 antifungal	 activity	 was	 evaluated	 against	 three	
fungal	species	namely	A.	niger,	F.	monoliforme	and	C.	albicans	
by	 agar	 well	 diffusion	method	 [17].	 The	 fungal	 strains	 were	
subcultured	separately	into	25	mL	of	sterilized	nutrient	broth	
and	 incubated	 for	one	day	 to	obtain	 the	 inoculums.	Each	 test	
compounds	 (1a‐h,	2a‐h)	 and	 standard	 drug	 (Bavistin)	 of	 10	
mg	was	dissolved	in	10	mL	of	DMSO	to	get	a	concentration	of	1	
mg/mL	and	 further	diluted	 to	 get	 a	 final	 concentration	of	30	
μg/mL.	 Molten	 media	 of	 Sabouraud	 agar	 of	 10‐15	 mL	 was	
poured	 into	 the	 petriplates	 and	 allowed	 to	 solidify.	 Fungal	
subculture	 was	 inoculated	 on	 the	 solidified	 media.	 With	 the	
help	of	6	mm	cork	borer,	the	cups	were	punched	and	scooped	
out	 of	 the	 set	 agar.	 The	 cups	 of	 inoculated	 plates	were	 then	
filled	 with	 0.1	 mL	 of	 the	 test	 solution,	 bavistin	 solution	 and	
DMSO	(negative	control).	The	plates	were	allowed	to	stay	for	3	
days	 at	 room	 temperature	 and	 zone	 of	 inhibition	 (mm)	was	
then	measured.	
	
2.3.2	Antioxidant	activity	
	
The	 scavenging	 activity	 of	 DPPH	 free	 radicals	 by	
synthesized	 compounds	 was	 determined	 according	 to	 the	
reported	method	 [18].	 Briefly,	 50	 µL	 of	 test	 compounds	was	
mixed	 at	 different	 concentrations	 (25,	 50,	 100,	 200	 and	 300	
µg/mL)	with	1	mL	of	0.1	mM	DPPH	in	methanol	solution	and	
450	µL	of	50	mM	Tris	HCl	buffer	(pH	=	7.4).	Methanol	(50	µL)	
only	 was	 used	 as	 the	 experimental	 control.	 After	 30	 min	 of	
incubation	at	room	temperature,	the	reduction	in	the	number	
of	 DPPH	 free	 radicals	 was	 measured	 by	 reading	 the	
absorbance	 at	 517	 nm.	 BHT	 (Butylatedhydroxyltoluene)	was	
used	 as	 control	 similar	 to	 test	 concentrations.	 Percent	
inhibition	was	calculated	from	the	equation	(1).	
	
(1)	
	
2.3.3.	Anti‐inflammatory	activity	
	
2.3.3.1.	Human	erythrocyte	suspension	
	
The	whole	 blood	was	 collected	 from	 a	 healthy	 volunteer	
who	 had	 not	 taken	 any	 NSAIDS	 for	 2	 weeks	 prior	 to	 the	
experiment	and	collected	in	heparinized	vacationer.	The	blood	
was	 washed	 three	 times	 with	 0.9%	 saline	 and	 centrifuged	
simultaneously	for	10	minutes	at	3000	rpm.	The	packed	cells	
were	washed	with	0.9%	saline	and	40%	(v:v)	suspension	made	
using	 isotonic	 phosphate	 buffer	which	was	 composed	 of	 154	
mM	NaCl	in	10	mM	Sodium	Phosphate	Buffer	at	pH	=	7.4	used	
as	stock	erythrocyte	or	RBC	suspension.		
	
2.3.3.2.	Hypotonic	solution‐induced	haemolysis	
	
The	membrane	 stabilizing	 activity	of	 the	compounds	was	
assessed	 according	 to	 the	 method	 [19]	 with	 slight	
modification.	 The	 test	 sample	 consisted	 of	 stock	 erythrocyte	
(RBC)	 suspension	 0.5	 mL	 mixed	 with	 5	 mL	 of	 hypotonic	
solution	 (50	mM	NaCl	 in	10	mM	Sodium	Phosphate	Buffered	
saline	 at	 pH	 =	 7.4)	 containing	 different	 concentrations	 of	
sample	 (25,	 50,	 100,	 200	 and	 300	 µg/mL).	 The	 control	
consisted	 of	 0.5	 mL	 RBC	 suspension	 mixed	 with	 5	 mL	 of	
hypotonic	 buffered	 solution	 alone.	 The	 standard	 drug	
acetylsalicylic	 was	 treated	 similar	 to	 test	 concentration.	 The	
experiment	 was	 carried	 out	 in	 triplicate.	 The	mixtures	 were	
incubated	for	10	minutes	at	room	temperature,	centrifuged	for	
10	 minutes	 at	 3000rpm	 and	 absorbance	 of	 the	 supernatant	
was	 measured	 spectrophotometrically	 at	 540	 nm.	 The	
percentage	inhibition	of	haemolysis	or	membrane	stabilization	
was	calculated	by	following	equation.		
	 		
% Inhibition of haemolysis =
A1 ‐ A2
A1
×100
  (2)	
	
where,	A1	=	Absorbance	of	hypotonic	buffered	solution	alone,	
A2	 =	 Absorbance	 of	 test/standard	 sample	 in	 hypotonic	
solution.	
	
3.	Results	and	discussion	
	
3.1.	Chemistry	
	
QZN	 1	 and	 QZN	 2	 were	 synthesized	 following	 the	
procedure	 described	 earlier	 method	 [20‐22]	 starting	 from	
anthranilamide	and	succinic	anhydride	or	maleic	anhydride	to	
obtain	propanoic	acid	analogue	or	butanoic	acid	analogue.		
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Table	1.	Antibacterial	and	antifungal	activities	of	the	compounds.	
Entry	 Antibacterial	activity	a,b,c	 Antifungal	activity	a,b,d	
S.	typhimurium	 E.	aerogenes	 K.	pneumonia E.	coli C.	albicans F.	moniliforme	 A.	niger
1	 4±0.3	 4±0.1	 5±0.1	 4±0.2	 3±0.3	 3±0.1	 4±0.1	
1a	 14±0.2	 16±0.7	 10±0.6	 10±0.8	 15±0.9	 11±0.4	 11±0.7	
1b	 10±0.3	 11±0.5	 8±0.2 7±0.1 11±0.3 8±0.1	 9±0.2
1c	 12±0.4	 14±0.3	 10±0.1 9±0.4 13±0.1 9±0.4	 10±0.6
1d	 14±0.6	 18±0.1	 14±0.1 13±0.4 17±0.2 13±0.3	 14±0.2
1e	 16±0.2	 20±0.2	 16±0.4 17±0.1 19±0.5 17±0.1	 18±0.3
1f	 18±0.1	 21±0.4	 20±0.8 20±0.4 21±0.2 20±0.3	 21±0.4
1g	 21±0.6	 25±0.2	 21±0.7 22±0.2 25±0.8 21±0.4	 23±0.2
1h	 20±0.5	 23±0.7	 18±0.4	 19±0.4	 23±0.2	 19±0.1	 20±0.3	
2	 4±0.2	 3±0.2	 3±0.1	 2±0.1	 2±0.2	 3±0.2	 4±0.2	
2a	 13±0.3	 14±0.3	 9±0.4	 8±0.40	 13±0.8	 9±0.3	 9±0.8	
2b	 8±0.4	 9±0.1	 7±0.2 6±0.1 9±0.2 6±0.1	 7±0.1
2c	 10±0.4	 13±0.5	 9±0.1	 9±0.3	 11±0.1	 7±0.2	 8±0.3	
2d	 13±0.3	 16±0.3	 13±0.3 12±0.2 15±0.4 11±0.4	 12±0.2
2e	 15±0.4	 18±0.2	 14±0.4 15±0.4 17±0.1 15±0.1	 16±0.4
2f	 17±0.6	 20±0.4	 19±0.1 18±0.2 20±0.3 19±0.4	 20±0.4
2g	 20±0.4	 23±0.7	 20±0.3 20±0.7 24±0.7 19±0.2	 21±0.3
2h	 18±0.3	 21±0.3	 16±0.4 17±0.1 21±0.1 17±0.3	 18±0.2
Std	 11±0.4	 13±0.6	 12±0.4	 13±0.2	 14±0.5	 11±0.3	 13±0.2	
a	Values	are	mean	of	three	determinations,	the	ranges	of	which	are	<5%	of	the	mean	in	all	cases.	
b	Zone	of	inhibition	in	mm.	
c	Std:	Streptomycin.	
d	Std:	Bavistin.	
	
These	quinazolinones	(1	and	2)	were	conjugated	to	amino	
acid	 methyl	 esters	 using	 EDCI/HOBt	 as	 coupling	 agent	 and	
NMM	 as	 base	 in	 solution	 (Scheme	 1).	 Completion	 of	 the	
reaction	 was	 confirmed	 by	 TLC	 and	 later	 by	 spectroscopic	
techniques	 like	 IR,	 NMR	 and	MS.	 The	 stretching	 frequencies	
appeared	 at	 1630‐1644	 (C=O)	 and	 3300	 cm‐1	 (NH)	 in	 IR	
spectra	and	in	NMR	spectra	the	peak	appeared	at	δ	~6.65	ppm	
as	a	doublet	(NH)	and	the	absence	of	COOH	peak	confirms	the	
conjugation.	 Further,	 the	mass	 values	 obtained	were	 in	 good	
agreement	 with	 the	 structures	 assigned.	 The	 presence	 of	 all	
requisite	peaks	and	absence	of	extraneous	peaks	confirms	the	
synthesis.	
	
3.2.	Antimicrobial	studies	
	
The	 efficiency	 of	 synthesized	 quinazolinones	 as	
antimicrobials	were	evaluated	against	various	strains	of	Gram	
negative	bacteria	like	S.	typhimurium,	E.	aerogenes,	E.	coli	and	
K.	pneumoniae	 followed	by	antifungal	studies	against	A.	niger,	
F.	moniliforme	and	C.	albicans	 following	agar	dilution	method.	
Zone	of	 inhibition	(mm)	values	are	presented	 in	Table	1.	The	
standard	 drugs	 streptomycin	 and	 bavistin	 were	 used	 as	
standards	 for	 antibacterial	 and	 antifungal	 activities,	
respectively.		
All	 the	 synthesized	 conjugates	 (1a‐h	 and	 2a‐h)	 showed	
good	 antimicrobial	 activity	 whereas	 the	 corresponding	
starting	 materials	 did	 not	 show	 any	 activity.	 This	 clearly	
testifies	 that	 conjugation	 definitely	 improves	 the	 activities	 of	
parent	 molecules	 (1	 and	 2).	 Compounds	 1e‐h	 and	 2e‐h	
showed	excellent	antimicrobial	activities	much	better	than	the	
standards	used.	Whereas	the	compounds	1a,	1c,	1d,	2a,	2c	and	
2d	 exhibited	 comparable	 activities	 to	 that	 of	 the	 standards	
used.	
Structure‐activity	 relationship	 suggested	 that	 the	
antimicrobial	 activity	 of	 a	 particular	 molecule	 is	 apparently	
governed	 by	 the	 side	 chain	 of	 amino	 acids.	 The	 most	 active	
analogues	1g	 and	2g	 consist	 of	 tryptophan	which	 has	 indole	
ring	 as	 its	 side	 chain.	 The	 activity	 may	 be	 due	 to	 its	
hydrophobic	 nature	 and	 the	 acid‐base	 character	 of	 indole	
nucleus.	The	compounds	1h	and	2h	got	second	position	among	
the	 series	 which	 have	 pyrrolidine	 ring	 of	 proline.	 The	 five	
membered	ring	of	proline	facilitates	 in	 improving	the	activity	
which	 could	 be	 due	 to	 steric	 conformation	 of	 this	 ring.	
Compounds	with	 phenylalanine	 and	 tyrosine	 are	 also	 having	
good	 activity	 which	 may	 be	 attributed	 to	 the	 presence	 of	
aromatic	 phenyl	 ring	 and	 phenolic	 side	 chain,	 respectively.	
This	 confirms	 our	 earlier	 observations	 that	 aromatic	 amino	
acids	 play	 an	 important	 role	 in	 improving	 the	 activity	 [23].	
Whereas	 the	 other	 amino	 acids	 derivatives	 like	 glycine	
(1a/2a)	 and	 serine	 (1d/2d)	 were	 also	 active	 which	may	 be	
due	to	their	simple	side	chain	functionalities.	The	conjugation	
of	 alanine	and	valine	were	 less	 active	 compared	 to	 reference	
standards	 may	 be	 due	 to	 steric	 hindrance	 of	 aliphatic	 side	
chains.	
	
3.3.	In‐vitro	antioxidant	activity	
	
Evaluation	of	antioxidant	activity	of	the	newly	synthesized	
analogues	was	done	by	2,2‐diphenyl‐1‐picryl‐hydroxyl	(DPPH)	
radical	 scavenging	 activity.	 The	 antioxidant	 properties	 were	
expressed	as	50%	inhibitory	concentration	 IC50	values	 (Table	
2).	
Quinazolinones	 scaffolds	 1	 and	2	 exhibited	 poor	 activity	
and	 upon	 conjugation	 with	 amino	 acids	 improved	 their	 free	
radical	 scavenging	 ability.	 Compounds	 1f,	 2f,	 1g	 and	 2g	
showed	 excellent	 free	 radical	 scavenging	 property	 with	 IC50	
values	35,	20,	40	and	30	µg/mL	respectively,	much	better	than	
the	standard	BHT	(IC50	45	µg/mL).	This	may	be	explained	on	
the	 basis	 that	 electron	 donating	 indole	 of	 tryptophan	
possesses	 good	 antioxidant	 and	 free	 radical	 scavenging	
properties	 which	 is	 in	 great	 agreement	 with	 earlier	 results	
[24].	In	addition,	indole	skeleton	has	been	reported	to	act	as	a	
protective	agent	in	different	models	of	oxidative	stress	both	in	
vivo	and	in	vitro	[25].	Further,	the	presence	of	phenolic	‐OH	of	
tyrosine	 may	 be	 responsible	 for	 high	 activity	 of	 tyrosine	
containing	 analogues	 which	 is	 also	 in	 good	 agreement	 with	
earlier	report	[26].		
	
3.4.	In	vitro	anti‐inflammatory	activity	
	
All	 the	 synthesized	 compounds	 were	 evaluated	 for	 their	
anti‐inflammatory	 activity	 using	 human	 erythrocytes.	 A	
substantial	 number	 of	 compounds	 have	 been	 identified	
exhibiting	 good	 to	 moderate	 inhibitory	 activity	 compared	 to	
standard	drug	aspirin.	IC50	was	determined	for	the	compounds	
showing	 more	 than	 50%	 inhibition	 concentration	 (Table	 2).	
Among	 the	 conjugates,	 phenylalanine	 and	 tryptophan	
conjugated	 heterocycles	 exhibited	 good	 activity	 compared	 to	
standard	 drug.	 This	may	 be	 due	 to	 the	 presence	 of	 aromatic	
and	hydrophobic	indole	group	in	tryptophan.	The	tyrosine	and	
proline	 analogues	 exhibited	moderate	 activity	which	may	 be	
due	 to	 the	 presence	 of	 phenolic	 group	 and	 five	 membered	
pyrrolidine	ring	system,	respectively.	
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Table	2.	Antioxidant	and	Anti‐inflammatory	of	the	conjugates.	
Entry	 Antioxidant	activity	a,b,	IC50	(µg/mL) Anti‐ inflammatory	activity	a,c,	IC50	(µg/mL)
1	 >300	 >300
1a	 >300	 >300
1b	 230±2.0	 >300
1c	 270±1.2	 >300
1d	 175±1.1	 >300
1e	 170±1.3	 52±0.6
1f	 35±0.9	 86±0.9	
1g	 40±1.0	 40±0.4
1h	 75±1.2	 88±0.9	
2	 285±1.2	 >300	
2a	 >300	 >300	
2b	 230±1.4	 >300
2c	 245±1.9	 >300
2d	 160±1.1	 >300
2e	 290±1.8	 44±0.9
2f	 20±0.5	 84±0.8
2g	 30±0.9	 38±0.5
2h	 95±1.0	 88±0.3	
Std	 45±1.2	 10±0.8
a	Values	are	mean	of	three	determinations,	the	ranges	of	which	are	<5%	of	the	mean	in	all	cases.	
b	Std:	Butylated	hydroxyl	toluene.	
c	Std:	Aspirin.	
	
Compounds	with	tryptophan,	tyrosine	and	proline	showed	
excellent	 antimicrobial,	 antifungal,	 antioxidant	 and	 anti‐
inflammatory	 activities.	 Whereas	 compounds	 with	 phenyl	
alanine	 exhibited	 good	 antibacterial,	 antifungal	 and	 anti‐
inflammatory	 activities.	 Further	 compounds	 with	QZN	1	 are	
more	 active	 than	 QZN	 2	 with	 respect	 to	 antibacterial	 and	
antifungal	 side	 chains.	 On	 the	 other	 hand,	 QZN	 2	 linked	
conjugates	 exhibited	 superior	 antioxidant	 and	 anti‐inflam‐
matory	activities	over	QZN	1	analogues.	This	small	but	definite	
difference	in	activity	clearly	indicates	the	importance	of	length	
of	side	chain	in	quinazolinones.	
	
4.	Conclusion	
	
The	methyl	 ester	 amino	 acids	 conjugated	 quinazolinones	
were	 synthesized	 and	 appraised	 for	 their	 efficacy	 as	
antibacterial,	 antifungal,	 antioxidant	 and	 anti‐inflammatory	
activities.	From	the	results,	it	may	be	summarized	that	some	of	
the	analogues	are	highly	active	than	the	standards	particularly	
tryptophan,	tyrosine	and	proline.	This	study	is	crystallizing	in	
that	 the	 presence	 of	 side	 chain	 functionalities	 in	 the	 amino	
acids	 of	 the	 conjugates	 renders	 the	 moieties	 more	 potent.	
Further,	compounds	with	QZN	1	are	more	active	 than	QZN	2	
with	 respect	 to	 antibacterial	 and	 antifungal	 studies.	 On	 the	
other	 hand,	 QZN	 2	 linked	 conjugates	 exhibited	 superior	
antioxidant	 and	 anti‐inflammatory	 activities	 over	 QZN	 1	
compounds.		
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